EMA/751065/2011

European Medicines Agency decision

P/248/2011

of 25 October 2011

on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (EMEA-000467-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/248/2011

of 25 October 2011

on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (EMEA-000467-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/79/2010 issued on 7 May 2010,

Having regard to the application submitted by Eisai Ltd on 30 June 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 September 2011, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for perampanel, tablet, oral suspension, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Eisai Ltd, European Knowledge Centre, Mosquito Way, AL10 9SN Hatfield, United Kingdom.

Done at London, 25 October 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)

EMA/PDCO/611324/2011

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000467-PIP01-08-M01

Scope of the application

Active substance(s):

Perampanel

Condition(s):

Treatment of treatment-resistant epilepsies (localisation-related or generalised epilepsies and age-related epilepsy syndromes)

Pharmaceutical form(s):

Tablet

Oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Eisai Ltd

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eisai Ltd submitted to the European Medicines Agency on 30 June 2011 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/79/2010 issued on 7 May 2010.

The application for modification proposed changes to the agreed paediatric investigation plan and to the timelines.

The procedure started on 13 July 2011.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Icelandic and the Norwegian Paediatric Committee member(s) agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 9 September 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of treatment-resistant epilepsies (localisation-related or generalised epilepsies and age-related epilepsy syndromes)

2.1.1. Indication(s) targeted by the PIP

Adjunctive therapy in patients with refractory partial onset seizures including secondarily generalised seizures.

Adjunctive therapy in patients with other paediatric epilepsies.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Tablet

Oral suspension

2.1.4. Studies

Area	**Number of studies**	**Description**
Quality	1	1. Development of an oral liquid formulation (< 0.5mg/ml) and a dosing device suitable for treatment of children of all ages including preterm neonates.
Non-clinical	1	2. 33-week oral gavage toxicity study in the juvenile dog.
Clinical	9	3. Pooled subgroup analyses of the efficacy, pharmacokinetics and safety of perampanel in the adolescent population included in three double-blind, placebo-controlled studies in patients with refractory partial seizures. 4. Open-label extension to double-blind, placebo-controlled, dose-escalation, parallel-group studies to evaluate the efficacy, pharmacokinetics and safety of perampanel as adjunctive therapy in adolescents and adults with refractory partial seizures. 5. Randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension phase to evaluate the effect of perampanel on cognition, safety, tolerability and pharmacokinetics when administered as an adjunctive therapy in adolescents with inadequately controlled partial onset seizures.

Area	Number of studies	Description
		6. Randomized, open-label, crossover study to demonstrate relative bioavailability between a 4 mg oral suspension of perampanel and a 4 mg tablet of perampanel in healthy adult subjects. 7. Open-label pilot study with an extension phase to evaluate the pharmacokinetics, and to generate preliminary safety, tolerability, and efficacy data of perampanel oral suspension as an adjunctive treatment in paediatric subjects with epilepsy from 2 to less than 12 years of age. 8. Exploratory, open-label study with an extension phase to evaluate preliminary efficacy, safety and tolerability of perampanel administered as an adjunctive therapy in paediatric patients (age 1 month to less than 18 years) with childhood epilepsy. 9. Randomized, double-blind, placebo-controlled, dose-escalation, parallel-group study with an extension phase to evaluate the efficacy, safety and tolerability of perampanel suspension and tablets when administered as an adjunctive therapy in paediatric and adolescent patients (age 2 to less than 18 years) with partial seizures. 10. Open-label, multiple-dose study to explore the safety, tolerability and pharmacokinetics of perampanel as an adjunctive therapy in neonates with seizures, aged from birth to less than 28 days, followed by an open label extension study (up to 1 year). 11. Open-label pilot study with an extension phase to evaluate the pharmacokinetics, and to generate preliminary safety, tolerability, and efficacy data of perampanel oral suspension as an adjunctive treatment in paediatric subjects with epilepsy from 1 to less than 24 months of age.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No.
Date of completion of the paediatric investigation plan:	By April 2021.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.